Media coverage about Zosano Pharma (NASDAQ:ZSAN) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zosano Pharma earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.8144491076847 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Separately, ValuEngine lowered Zosano Pharma from a “sell” rating to a “strong sell” rating in a report on Tuesday, February 27th.
Shares of ZSAN traded down $0.14 during trading hours on Thursday, reaching $4.24. 2,527 shares of the company traded hands, compared to its average volume of 929,068. The firm has a market cap of $54.00 million, a P/E ratio of -0.25 and a beta of 1.93. Zosano Pharma has a fifty-two week low of $3.61 and a fifty-two week high of $30.00.
Zosano Pharma Company Profile
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.